Delving into the Latest Updates on Metenkefalin/Tridecactide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Enkorten

Target

δ opioid receptor x κ opioid receptor

Action

agonists, stimulants, modulators

Mechanism

δ opioid receptor agonists(δ-opioid receptor agonists), κ opioid receptor agonists(Kappa opioid receptor agonists), Leukocytes stimulants

+ [1]

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple Sclerosis

Inactive Indication

COVID-19Multiple Sclerosis, Relapsing-Remitting

Originator Organization

Farmicija Dd

Active Organization

Farmicija Dd

Inactive Organization

Bosnalijek dd

Bosnalijek d.d.

License Organization-

Drug Highest PhaseApproved

First Approval Date

Bosnia and Herzegovina (01 Feb 2010),

Multiple Sclerosis

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 86477

The sequence is quoted from: *****

A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple sclerosis is a chronic autoimmune, inflammatory neurological disease of the central nervous system. It is the most common disabling neurologic disease of young people. This study is planned for the evaluation of efficacy, safety and tolerability of neuropeptide combination of metenkefalin and tridecactide (EK-12) as compared to INF beta-1a (REBIF®) in patients with RRMS. The primary objective of this study is to prove the superiority of efficacy of neuropeptide combination of metenkefalin and tridecactide (EK-12) compared to INF beta-1a (REBIF®) in patients with RRMS on the basis of annualized protocol defined relapse rate by 144 weeks.

Start Date26 Mar 2019

Sponsor / Collaborator

Bosnalijek d.d.

[+1]

100 Clinical Results associated with Metenkefalin/Tridecactide

Login to view more data

100 Translational Medicine associated with Metenkefalin/Tridecactide

Login to view more data

100 Patents (Medical) associated with Metenkefalin/Tridecactide

Login to view more data

2

Literatures (Medical) associated with Metenkefalin/Tridecactide

01 Sep 2023·Environmental science and pollution research international

Enhancement of electrokinetic-phytoremediation by Ophiopogon japonicus: stimulation of electrokinetic on root system and improvement of polycyclic aromatic hydrocarbon degradation.

Article

Author: Yuan, Xi ; Liu, Huigang ; Zhang, Zhaonian ; Xi, Ying ; Li, Ming ; Johnson, David M ; Xu, Tao ; Li, Kun ; Li, Meng ; Huang, Yingping

Root systems are sensitive to voltage and tend to improve the degradation of organic pollutants by promoting the root exudates and increasing microbial enzyme activity in the rhizosphere under the effect of electrokinetic. In this study, electrokinetic-assisted phytoremediation (EKPR) was applied for the remediation of soil containing phenanthrene (PHE) and pyrene (PYR). Direct current (DC) voltage (1 V cm^-1) was applied across the soils for 30 days following 3 treatment schedules (0 h, 4 h, and 12 h per day), referred to as treatments EK0, EK4, and EK12. Electrokinetic assistance improved phytoremediation. Compared to EK0, the removal of PHE and PYR increased by 51.79% and 45.07% for EK4 and by 43.18% and 38.75% for EK12. The applied voltage promoted root growth, stimulated the root exudate release, and increased accumulation of PHE and PYR by plants, and the effect was most pronounced in treatment EK4. Catalase and urease activities in rhizosphere soil also increased, by respective increments of 44.51% and 40.86% for EK4 and by 28.53% and 21.24% for EK12. In this study, we demonstrated that a low voltage applied for an appropriate duration (4 h per day) improves removal of PAHs by stimulating root growth, promoting the root exudate release and enhancing enzyme activity in the microbiome of rhizosphere soil.

01 Jan 2008·Medicinski arhiv

[Pharmacodynamic properties of a combination of met-enkephalin and alpha 1-13 adrenocorticotropic hormone].

Review

Author: Mulabegović, Nedzad ; Rakanović-Todić, Maida

ENKORTEN is newly registered drug in Bosnia and Herzegovina. It consists of two peptide components: met-enkephalin and alpha 1-13-corticotropine (alpha-ACTH 1-13), previously called alpha-melanocyte-stimulating hormone-like (alpha-MSH-like) Met-enkephalin and alpha-MSH exhibited cytoprotective effects individually and statistically significant additive effect was registered when both peptides were applied in combination on the model of ethanol induced gastric lesions in rats. Combination has immunomodulatory effects. Method of selective immunomodulation with antigens and peptides in immunological mediated diseases and malignant tumors is directed towards long-term remission without so many adverse effects characteristic for immunosuppressive drugs. Adverse reactions registered for so long with ENKORTEN were mild, reversible and usually developed during and immediately after drug application.

100 Deals associated with Metenkefalin/Tridecactide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N07XX	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	Bosnia and Herzegovina	Farmicija Dd	01 Feb 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Phase 1	Turkey	Bosnalijek d.d.	26 Mar 2019
COVID-19	Preclinical	Bosnia and Herzegovina	Bosnalijek dd	01 May 2020
COVID-19	Preclinical	Bosnia and Herzegovina	Bosnalijek d.d.	01 May 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.


No Data

Metenkefalin/Tridecactide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation